Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
3. Women vs. men: Gender-based research at ESC 2012
Women with heart failure are less likely to receive treatment, more likely to survive TAVI and less and more prone to stroke than men, according to research presented at the 2012 European Society of Cardiology Congress.
2. Edwards Lifesciences insiders keep selling
No Edwards Lifesciences insiders have bought company stock since April 2012, during which time EW shares have gained nearly 40%.
1. Shock study calls into question decades of intra-aortic balloon counter-pulsation
Results from the IABP-Shock II trial, the largest ever performed in cardiogenic shock, finds no benefit for intra-aortic balloon pump therapy in MI patients, calling into question a practice used for decades with one of the oldest medical devices.
